Showing results (411-420 of 468) with videos related to

Sort By:
Pageof 47
American Heart Journal|April 30, 2017
Differential occurrence, profile, and impact of first recurrent cardiovascular events after an acute coronary syndromeConnie N Hess, Robert M Clare, Megan L Neely, et al.
Mbio|August 14, 2025
AcrIF11 is a potent CRISPR-specific ADP-ribosyltransferase encoded by phage and plasmidDaphne F Chen, Leah T Roe, Li Yuping, et al.
Clinical Cardiology|July 29, 2016
Dual Antiplatelet Therapy and Outcomes in Patients With Atrial Fibrillation and Acute Coronary Syndromes Managed Medically Without Revascularization: Insights From the TRILOGY ACS TrialLarry R Jackson, Jonathan P Piccini, Derek D Cyr, et al.
American Heart Journal|September 26, 2006
The impact of emergency department structure and care processes in delivering care for non-ST-segment elevation acute coronary syndromesRajendra H Mehta, L Kristin Newby, Yogin Patel, et al.
European Heart Journal|April 3, 2009
Prior polyvascular disease: risk factor for adverse ischaemic outcomes in acute coronary syndromesDeepak L Bhatt, Eric D Peterson, Robert A Harrington, et al.
Journal of the American College of Cardiology|April 23, 2003
Combination reperfusion therapy with eptifibatide and reduced-dose tenecteplase for ST-elevation myocardial infarction: results of the integrilin and tenecteplase in acute myocardial infarction (INTEGRITI) Phase II Angiographic TrialRobert P Giugliano, Matthew T Roe, Robert A Harrington, et al.
The American Journal of Cardiology|October 24, 2006
Temporal trends in the use of early cardiac catheterization in patients with non-ST-segment elevation acute coronary syndromes (results from CRUSADE)Pierluigi Tricoci, Eric D Peterson, Jyotsna Mulgund, et al.
European Heart Journal|February 27, 2004
Creatine kinase-MB elevation after percutaneous coronary intervention predicts adverse outcomes in patients with acute coronary syndromesM T Roe, K W Mahaffey, R Kilaru, et al.
American Heart Journal|August 10, 2016
Health-related quality of life outcomes with prasugrel among medically managed non-ST-segment elevation acute coronary syndrome patients: Insights from the Targeted Platelet Inhibition to Clarify the Optimal Strategy to Medically Manage Acute Coronary Syndromes (TRILOGY ACS) trialPadma Kaul, E Magnus Ohman, J David Knight, et al.
JAMA|November 3, 2012
Platelet function during extended prasugrel and clopidogrel therapy for patients with ACS treated without revascularization: the TRILOGY ACS platelet function substudyPaul A Gurbel, David Erlinge, E Magnus Ohman, et al.
Pageof 47